Acute leukemias (AL) are classified according to their commitment to either the myeloid or lymphoid lineage. Immunophenotyping for various intra-and extracellular cell lineagespecific markers is an important feature in differentiating between acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). In about 4% of AL cases it is not clear whether blasts are derived from myeloid or lymphoid progenitors and are classified as AL of ambiguous lineage. AL with biphenotypic characteristics represent a subgroup with a worse prognosis, which can be partly explained by a higher incidence of the Philadelphia chromosome or other complex cytogenetic aberrancies; these patients present more often with extramedullar localization of disease, which urges for more intensive treatment protocols including central nervous system prophylaxis. The question whether these patients benefit from an (intensified) ALL or AML protocol is still unresolved due to lack of solid randomized treatment protocols. [1] [2] [3] [4] [5] In 1995 the European group for immunological characterizing of AL (EGIL) presented guidelines for classification of AL with biphenotypic marker expression. These criteria were incorporated in the WHO2001 guidelines for classifying AL of ambiguous lineages. For many years the EGIL guidelines offered a platform for harmonizing diagnostic criteria important for prognosis and clinical outcome measurements. 6, 7 In 2008 new WHO criteria were proposed for classification of acute leukemias of ambigious lineages. 8 For acute leukemias with a mixed phenotype (MPAL), these new criteria implicated significant modification with the EGIL scoring system with potential implications for treatment and clinical research. 8 For instance, in WHO2008 both bilineal and biphenotypic AL are classified as a MPAL, whereas these were distinct entities in the EGIL. Furthermore, single expression of cytoplasmatic myeloperoxidase (cytMPO) or CD3 (surface or intracellular) is now regarded as sufficient to determine whether blasts belong to the myeloid or T-cell lineage, respectively. AL that express both cytMPO and CD19 are now diagnosed as MPAL depending on the expression of cytCD79a, CD10 or cytCD22. In contrast to the EGIL, the WHO2008 excludes AL with certain cytogenetic aberrancies or clinical presentations from MPAL: AL with t(8;21), t(15;17) or inv(16) are classified as AML with recurrent cytogenetic abnormalities despite their immunophenotypic marker expression. Furthermore, AL with FGFR1 mutations, CML-blast crises, AL with MDS pre-phase and therapy-related AL are separate entities according to WHO2008 criteria.
These new criteria are likely to change diagnosis and hence therapeutic considerations in various patients. To investigate this issue, we retrospectively analyzed a cohort of 517 patients admitted to our hospital with acute leukemia from 2000 to 2008 and compared diagnosis by applying both EGIL and WHO2008 criteria.
Immunophenotyping of bone marrow samples was performed as part of regular clinical diagnostic procedures. Shortly, after bulk red-cell lysis and antibody incubation at room temperature, expression levels of B-cell, T-cell and myeloid lineage-specific and defining markers on blasts were determined by four-color flow cytometry on a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA). Cells were characterized for the following markers: CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD19, CD20, CD22, CD25, CD33, CD34, CD36, CD42b, CD45, CD56, CD61 CD65, CD71, CD90, CD117, CD133 and HLA-DR. For analysis of cytoplasmic markers, cells were fixed with paraformaldehyde and subsequently permeabilized with Facs Lyse (Becton Dickenson, San Jose, CA, USA) followed by staining for CD3, IgM, CD79a, TdT and MPO. All antibodies were obtained from: Becton Dickenson, Zebra biosciences (Enschede, The Netherlands), Dako (Glostrup, Denmark) or Sanquin (Amsterdam, The Netherlands). Results were analyzed using CellQuest Pro software (Becton Dickenson). Blasts were characterized by low side scatter, diminished or low CD45 expression and CD34 expression. In case of CD34-negative AL, blasts were gated using other immature markers such as CD117, CD133, CD10 and cytIgM. In our analysis we used a cut off of 20% marker positivity, as specified in the EGIL criteria. 8 In the WHO2008, cell line-specific markers CD19 and CD3 should be highly expressed on blasts (expression equal or higher than the normal T or B cells within the patient's sample) to assign a certain lineage positive in case of an MPAL. We considered blasts strongly positive ('s') for a certain marker if at least 20% of the population was positive as compared with the appropriate isotype control combined with a mean fluorescence intensity as high as, or higher than normal B or T cells within the same sample. Weak expression ('w') is defined when the expression level does not reach expression of corresponding normal cells. In cases where normal B or T cells were absent, we compared the expression level with historical normal controls. Molecular diagnostic procedures were performed as part of regular clinical diagnostic procedures. Quick frozen cell pellets were used for determination of presence of translocations t(9;22), t(8;21), t(15;17), MLL, FLT3-ITD by PCR following institutional guidelines (www.modhem.nl).
Out of 517 AML patients 26 (5.0%) could be classified as BAL (EGIL), MPAL (WHO2008) or both with a B-cell/myeloid (B/My) combined phenotype (summarized in Table 1a ). Of those, seven patients (UPN 1-4 and 6-8) showed an expression profile, which allowed classification for both MPAL and BAL. As AML with t(8;21) frequently show coexpression of CD19 and cCD79a next to the myeloid markers CD13, CD33 and MPO, UPN 6-8 are classified as AML with t(8;21) considering WHO2001 and as AML with recurrent cytogenetic abnormality according to the WHO2008 criteria.
Based on medical history UPN 11 and 12 were classified as AML with myelodysplasia-related changes and UPN 9 and 10 as a BC-CML, excluding these patients as possible MPAL. Despite presence of t(9;22), UPN 1 and 5 were not classified as BC-CML because of absence of a CML pre-phase; these AL of ambiguous lineage substitute a subgroup of MPAL. There are only two patients, UPN 5 and 27, who are considered an MPAL in WHO2008 guidelines based on expression of solely cytMPO; these were classified as a B-and T-ALL, respectively, following EGIL criteria. In our cohort we did not find any cases with monocytoid differentiation (based on expression of CD14, CD11c, CD45 bright, HLA-DR and side and forward light scatter properties) combined with expression of lymphoid markers; especially not on those patients previously diagnosed as BAL. Although we did not include CD36 and CD64 in our analysis, detection of CD14 and CD11c is considered as adequate in assigning the monocytoid lineage.
One argument to change the criteria in the WHO2008 classification was to distinguish the lineage markers expressed on leukemic blasts that truly reflect the biphenotypic nature of cells from the markers, which are commonly seen on subtypes of AL. For instance pro-B-ALL and pre-pre-B-ALL often show expression of myeloid markers; UPN 25 and 26 showed, in absence of cytMPO, high expression of CD19 and cytCD79a combined with low expression of CD33, CD13 and CD15. Considering the EGIL guidelines these patients were classified as BAL, whereas in WHO2008 these patients have to be classified as B-ALL (Table 1a ).
In the EGIL and WHO2001 acute bilineal leukemias were classified as a distinct entity, whereas in the WHO2008 these are joined with biphenotypic AL as MPAL. In case of MPAL of bilineal origin (WHO2008) or bilineal AL (EGIL) there should be two or more different populations in which at least one of these meets the immunophenotypic criteria for AML (with the exception that the population does not need to comprise at least 20%). In our cohort, five AL (1%) with a bilineal phenotype were found. As criteria for bilineal origin are the same for EGIL and WHO2008, data are not shown.
Seven patients (1.4%) could be classified as BAL, MPAL or both with T-cell/myeloid (T/My) lineage (Table 1b) . Remarkably, only UPN 28 is considered a BAL and MPAL based on immunologic marker expression; nevertheless this patient was excluded from classification because of a known history of MDS.
UPN 34 and 35 showed positivity for three lineages and can be considered as a B/T/My AL following the EGIL criteria (Table 1c ). In the EGIL classification system, discrimination between T-and B-cell lineage is difficult to define because CD10 and cytTdT are cell lineage defining markers for both lineages. When CD10 and cytTdT are only scored once for either T or B lineage according to EGIL criteria instead of double scored for both lineages, no B/T mixed phenotype AL could be found in our cohort Sometimes, current criteria fail to classify AL as a T-ALL, B-ALL or AML, that is, in cases were CD3, CD19 and cytMPO are negative and a BAL might be considered based on other cell lineage defining markers. For example, UPN 29 is negative for cytMPO, cytCD3 and CD3, but expresses CD5, CD7, CD2, CD13, CD33 and CD117; WHO2008 guidelines do not elucidate whether this case should be considered T-ALL or AML. Similarly, UPN 13 and 14 are indecisive for B-ALL or AML. In these cases, former EGIL criteria might give further directions.
Overall, we can conclude that the WHO2008 classification has a clear diagnostic impact for AL that express different cell lineage-specific and defining markers. Considering EGIL criteria 30 of 517 AL (5.8%) were classified as BAL, whereas in WHO2008 only eight cases (1.5%) would have been classified as MPAL. BAL and MPAL cases did not fully coincide with each other, only 6 of 517 cases (1.1%) would have been classified as BAL as well as MPAL by EGIL and WHO2008 criteria, respectively. On the basis of our data almost all AL with combined myeloid and B or T characteristics are re-classified as ALL or AML in the new WHO2008 classification, which in the future will have an impact on therapeutic decision making.
Table 1a
Comparison of EGIL and WHO2008 in classification of acute leukemias with combined expression of B-cell and myeloid lineage markers Abbreviations: AML, acute myeloid leukemia; AL, acute leukemia; ALL, acute lymphatic leukemia; BAL, biphenotypic acute leukemia; cytMPO, cytoplasmic myeloperoxidase; cytTdT, cytoplasmic terminal deoxynucleotidyl transferase; CML-BC, chronic myleoid leukemia blast crisis; MPAL, mixed phenotype acute leukemia; NSE, Non-specific esterase; pos, positive; neg, negative; ND, not determined; xUPN, unique patient number.
Results are shown for those samples, which are scored positive for a biphenotypic acute leukemia corresponding to the EGIL criteria and/or for a mixed phenotype acute leukemia (MPAL) corresponding to the WHO2008 criteria. Discrimination is made between weak, heterogeneous or strong expression. Strong expression ('s') is defined as higher or as high as the expression on nonmalignant cells in the same sample or, known from healthy donors. Weak expression ('w') is defined when the expression level does not reach expression of corresponding normal cells. Heterogeneous and strong expression ('h, s') is defined when, next to a heterogenous expression, the cells with highest expression are as high or higher as the expression of non-malignant cells. Monoblastic appearance is defined by expression of at least CD14 or CD11c.
AML*, UPN 6, 7 and 8 are classified as AML with t(8;21) considering EGIL criteria; AL*, UPN 11, 12 & 28 are excluded from MPAL based on the classification as an MDS-related acute leukemia; AL**, for UPN 13, 14 and 29 it is not clear whether these should be classified as AML, ALL or MPAL in the WHO2008.
Letters to the Editor
The clinical significance of the WHO2008 criteria needs to be shown in prospective clinical studies.
